| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed28726de9f916f355f8adc331e736b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-999 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6df1cfb63ba5b39bda8bf025cbafba5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_488fa6072df017dc7bdce0c812efa9c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86c6797f93ed60421dcf63f1e33e9bf8 |
| publicationDate |
2021-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11135224-B2 |
| titleOfInvention |
Methods of sensitizing estrogen receptor positive (ER+) breast cancer cells to endocrine therapy |
| abstract |
Aspects of the technology are directed to a method of increasing sensitivity of estrogen receptor positive (ER + ) breast cancer cells to treatment with an endocrine therapy. The method involves selecting ER + breast cancer cells, and administering to the selected cells (i) one or more mammalian target of rapamycin (mTOR) inhibitors and (ii) one or more MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1) inhibitors in an effective amount to increase the sensitivity of the ER + breast cancer cells to treatment with the endocrine therapy. Methods of treating a subject having ER + breast cancer are also disclosed. |
| priorityDate |
2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |